SPACs Now Main Driver of Fundraising and New Growth in Cannabis
For U.S. cannabis companies looking to raise capital for operations that deal in a federally illegal substance, IPOs on American markets aren’t a viable option. Other traditional capital sources—banks, for example—are equally off limits. The constraints set up a perfect environment for special purpose acquisition companies (SPACs) to thrive—and thriving they are.
SPACs are well-suited to the rapidly evolving dynamics of the cannabis industry, allowing companies to list on a stock exchange earlier than they might be able to launch an IPO—primarily in Canada, though a few have landed on the NASDAQ. Because they represent significantly higher liquidity than other vehicles, SPACs attract risk-tolerant investors who typically avoid directly participating in cannabis ventures. Even top-tier firms J.P. Morgan and BMO Capital Markets have backed cannabis SPACs within the past year.
Related: Medical Cannabis to Grow 36% Through 2024
“SPACs have existed since the early 1990s in conventional markets but are only now gaining traction in cannabis,” said Christopher Jones, senior editor for mg Magazine. “With federal legalization potentially on the horizon and increasing pressure from large, well-funded Canadian entities, American companies need to find a way to scale now, not later. SPACs are a very attractive option.”
This year has seen explosive activity, with nine SPAC mergers totalling roughly $5 billion in qualifying transactions completed between January and August. In October, 22 cannabis SPACs sought a combined $3.9 billion in investment.
“We expect the pace of both launches and completions—along with the size of qualifying transactions—to pick up in 2022,” Jones said.
About mg Magazine:
Founded in 2015, mg Magazine is the media of record and industry authority for senior executives operating within the cannabis industry. Dubbed “weed’s hybrid of Forbes and Inc.,” mg serves its multi-platform audience in-depth features, business news, analysis, and other content designed to inspire, educate, and inform. mg is published by Incunabulum LLC. For more information, visit mgretailer.com.
Media Contact:
MATTIO Communications
Mel Trecha
mel@mattio.com
SOURCE mg Magazine
About Cannin: Your Cannabis Stocks Resource
78% of Cannin’s fundamentals prove true within 30 days or less on 100+ recommendations over the past 2 years.
Cannin is your #1 trusted resource for cannabis stocks. Our global team of experts evaluates all emerging cannabis stock investing opportunities. In fact, we aggregate hundreds of hours of financial research and provide tips on the best cannabis stocks for 2021.
Use Cannin as your resource for:
Market analysts expect the marijuana and hemp industry will have an annual value exceeding $75 Billion in the next decade. Is it too late to invest in marijuana stocks? No! This is the perfect time to invest.
Are you looking to buy stock in hemp companies or marijuana companies for 2021? If so, are you interested in new penny hemp stock companies? Or, looking for the best Canadian cannabis stocks to invest in? Maybe, you’re looking to leverage the power of algorithmic stock trading to beat the cannabis market? We can help.
Are you interested in cannabis stocks like Curaleaf, Trulieve, Aurora Cannabis, Charlotte’s Web, Canopy Growth, or Hemp Inc.?
Predict price movements of cannabis stocks several hours in advance with our proprietary algorithmic stock trading software.
- +30% Gains in 2020
- +49.8% Gains in 2019
- Backtested since 2012
In fact, we’re so confident you’ll love our algotrading cannabis stock signals, we’re willing to give you a one week risk-free trial to see it for yourself.
Profit from the best cannabis stocks – we’ll show you how at cannin.com.
